Table 4 Changes measured by OCT and ICGA in eyes that received PDT at the 12-month follow-up
From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Number of eyes (%) | Morphological changes |
|---|---|
9 (56.3%) | Subretinal fluids absorbed |
8 (53.3%) | PED resolved |
11 (61.6%) | Complete regression of polyps |
3 (16.7%) | Reduction in polyps |